• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, March 29, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Tenaya Therapeutics launches with the goal of curing heart disease

Bioengineer by Bioengineer
December 6, 2016
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new biopharmaceutical company, Tenaya Therapeutics Inc., will build on discoveries in cardiovascular disease research made at the Gladstone Institutes, concentrating on regenerative medicine and drug discovery for heart failure. The new company combines Gladstone's basic science expertise with the resources and translational know-how of the biotechnology industry.

Cardiovascular disease — including heart attacks and congenital heart defects — is the world's leading cause of death. Heart failure alone afflicts more than 20 million people around the world.

"When heart muscle is damaged, the body is unable to repair the dead or injured cells," explained Deepak Srivastava, MD, director of the Gladstone Institute of Cardiovascular Disease and a co-founder of the new company. "Right now, the only possible cure for heart failure is a heart transplant. We hope that this new venture will bring us closer to a more scalable cure."

"There has been limited commercial investment in the cardiac field, despite the remarkable progress made at Gladstone and elsewhere," added Stephen Freedman, PhD, vice president for corporate liaison and ventures at Gladstone. "Tenaya will advance some of the innovative work coming out of Gladstone, with the aim of developing new therapeutics for heart failure."

Tenaya is supported by a $50 million Series A financing from The Column Group. David Goeddel, PhD, a managing partner at The Column Group and a pioneer of the biotechnology industry, is the board chair of Tenaya. JJ Kang, PhD, an associate at The Column Group, is a board director and president of the new company.

"The key ingredients for a successful company are a great team and great ideas," said Goeddel. "With the stellar group of scientists that we've assembled, we're confident that we will be able to build something transformative from the cutting-edge research of the Gladstone Institutes."

Tenaya will leverage Gladstone's pioneering work in cellular reprogramming to search for cures for heart failure. One program will translate cellular reprogramming technology to the clinic to regenerate heart muscle cells in patients with heart failure. Other programs will use cellular models of heart disease created from stem cells to identify potential new drug targets.

The new company is the first formed out of BioFulcrum, an entrepreneurial initiative within Gladstone that takes a milestone driven approach to science. BioFulcrum aims to accelerate the discovery of cures by bringing together scientists, multiple non-profit institutions, and industry partners such as Goeddel, who sits on the board of BioFulcrum.

"Inspired by the collaborative research at BioFulcrum, we wanted to establish Tenaya to integrate new findings and tools in the cardiac field and advance them towards clinical translation," said Kang. "Our goal is to build a science-focused company that discovers novel therapies for heart failure patients."

###

Scientific co-founders of the company include Srivastava and Gladstone Investigators Benoit Bruneau, PhD, Bruce Conklin, MD, Sheng Ding, PhD, and Saptarsi Haldar, MD, as well as Eric Olson, PhD, from the University of Texas Southwestern Medical Center. Other Gladstone scientists will serve as scientific partners (Katherine Pollard, PhD, Todd McDevitt, PhD, Nevan Krogan, PhD) or founding employees of the company, including Kathy Ivey, PhD, former director of the Gladstone Stem Cell Core and the new director of research operations at Tenaya.

"The launch of Tenaya Therapeutics exemplifies Gladstone's fierce dedication to scientific discovery and to putting those discoveries on a path to pioneering new therapeutics," said Gladstone President R. Sanders "Sandy" Williams, MD, who is on the board of Tenaya. "Deepak assembled a group of investigators adept at discovery within Gladstone, and our novel BioFulcrum initiative accelerated their progress. Plus, in Dave Goeddel and JJ Kang from The Column Group, we found the perfect partners for this new enterprise."

About the Gladstone Institutes

To ensure our work does the greatest good, the Gladstone Institutes focuses on conditions with profound medical, economic, and social impact–unsolved diseases of the brain, the heart, and the immune system. Affiliated with the University of California, San Francisco, Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease.

Media Contact

Dana Smith
[email protected]
415-734-2532
@GladstoneInst

http://www.gladstone.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Figure 1

Senescence and extracellular vesicles: novel partners in vascular amyloidosis

March 29, 2023
Groundbreaking Lymphoma Tumor Model Paves Way for New Therapies

Groundbreaking lymphoma tumor model paves way for new therapies

March 29, 2023

Mimicking biological enzymes may be key to hydrogen fuel production

March 29, 2023

Downregulation of angulin-1/LSR induces malignancy in lung adenocarcinoma

March 29, 2023
Please login to join discussion

POPULAR NEWS

  • ChatPandaGPT

    Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform

    67 shares
    Share 27 Tweet 17
  • Northern and southern resident orcas hunt differently, which may help explain the decline of southern orcas

    44 shares
    Share 18 Tweet 11
  • Skipping breakfast may compromise the immune system

    43 shares
    Share 17 Tweet 11
  • Insular dwarfs and giants more likely to go extinct

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Senescence and extracellular vesicles: novel partners in vascular amyloidosis

Groundbreaking lymphoma tumor model paves way for new therapies

Mimicking biological enzymes may be key to hydrogen fuel production

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 48 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In